CellFE will be presenting a poster at the International Society of Gene and Cell Therapy (ISCT) Annual Meeting next week with a poster on Transfecting αβ T Cells with CRISPR-Cas9 RNP via microlfuidic method.
Todd Sulchek, PhD, Co-founder of CellFE and Head of the Sulchek BioMEMS & Biomechanics Lab at Georgia Tech, will be participating as a speaker…
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
CellFE announced it has raised $3.6 million in an initial Series Seed, co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures.
CellFE will participate in one of 15 funded projects as part of $9M in funding by the National Institute for Innovation in Manufacturing Biopharmaceuticals…
